Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DKP21102_B + DKP21102_A
- Development stage
- Unknown
- Lead developer
- Dongkwang Pharm
01
Overview
DKP21102_B + DKP21102_A is a **combination investigational drug regimen** developed by Dongkwang Pharm for the treatment of mixed dyslipidemia. It is designed to treat patients in whom LDL-C is well-controlled but triglyceride and HDL-C levels are not adequately managed by DKP21102_A alone. The specific identities and mechanisms of DKP21102_B and DKP21102_A are not disclosed in public clinical trial registries, but the combination is tested for further efficacy in lipid modulation beyond monotherapy.
- Brand names
- DKP21102DKP-21102DKP 21102
- Other names
- DKP21102_B + DKP21102_A
Beyond the preview
Go deeper on DKP21102_B + DKP21102_A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DKP21102_B + DKP21102_A.